|
|
Volumn 30, Issue 1, 2012, Pages 6-8
|
|
Safety profiles come to fore as more drugs approach MS market.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
FUMARIC ACID DERIVATIVE;
FUMARIC ACID DIMETHYL ESTER;
MONOCLONAL ANTIBODY;
DRUG APPROVAL;
HUMAN;
MULTIPLE SCLEROSIS;
NOTE;
PATIENT SAFETY;
PHASE 3 CLINICAL TRIAL (TOPIC);
ANTIBODIES, MONOCLONAL, HUMANIZED;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG APPROVAL;
FUMARATES;
HUMANS;
MULTIPLE SCLEROSIS;
PATIENT SAFETY;
|
|
EID: 84863312918
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0112-6c Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
